U.K. scientists and researchers are working on a new type of gene therapy that could revolutionize the treatment of diseases such as multiple sclerosis, Parkinson’s and Alzheimer’s.
The research was funded by the National Institutes of Health.
It was announced today at the American Society of Biochemistry and Molecular Biology annual meeting.
The team, led by the Harvard Medical School professor and senior author on the research, Dr. Steven C. Zwilling, is working to develop a gene therapy for the first time that would be able to target the DNA of a patient’s own cells to block the development of disease-causing mutations.
The treatment would be delivered through the delivery of a nanoparticle, which would attach to a target cell’s DNA and activate a gene.
The target cell then produces a copy of the gene, and the gene then replicates.
The new approach is far more efficient than other gene therapy approaches that use viruses to deliver a single gene into a patient, which is what Zwailing is working on with his team.
This type of treatment is known as gene-editing technology.
Gene therapy is the first approach that is designed to replace or replace genes with a different version of the same gene.
Zweilling’s team is working with researchers at the University of Texas Southwestern Medical Center, the National Institute of Neurological Disorders and Stroke and the University at Buffalo.
The researchers are also developing gene therapy to target a specific type of cancer known as pancreatic cancer.
Zwaill has previously shown that he has created a drug that can treat cancer by mimicking the genetic code of pancreatic tumors.
The University of Buffalo and the National Cancer Institute (NCI) funded the research.
The gene therapy, called CRISPR-Cas9, is a molecular-editable gene that can be inserted into a person’s DNA.
It is one of a growing group of gene therapies that can target specific DNA segments in a person.
The next generation of this technology is still in the development phase.
Researchers have also shown that it could be effective against the human papilloma virus, which causes cervical cancer.
Researchers say that the gene therapy has the potential to be used in a variety of different cancers.
One of the main challenges for gene therapy is to find a way to block mutations in the DNA that can trigger cancer development, Zwill said.
“We have developed a way of targeting specific DNA regions that are associated with cancer, but there are still a lot of challenges to overcome before we can see this technology in people,” Zwills said.
He and his colleagues are developing a new gene therapy approach that they believe could be used to treat pancreatic, colorectal, ovarian and lung cancers.
CRISPA-Cas1 gene therapy can also be used for other diseases, including those related to cardiovascular disease, immune and reproductive disorders, and Parkinson’s disease.